Newsbenzinga
These Analysts Slash Their Forecasts On EyePoint
· Published
Article summary
EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoint was not met, secondary endpoints showed progress. Analysts adjust price targets.
An excerpt from the original article.
Comments —
Loading comments…